ESCRS - PO664 - Two And Three Year Results After Preserflo Microshunt Implantation – Decreased Risk For Failure Over Time

Two And Three Year Results After Preserflo Microshunt Implantation – Decreased Risk For Failure Over Time

Published 2025 - 43rd Congress of the ESCRS

Reference: PO664 | Type: Free paper | DOI: 10.82333/pkzh-gv04

Authors: Ipek Tanyolac* 1 , Ahmet Kirgiz 1 , Efe Koser 1 , Sibel Ahmet 1 , Nilay Kandemir Besek 1

1Beyoglu Eye Training and Research Hospital,Istanbul,Türkiye

Purpose

Compared to trabeculectomy, there’s still a lack for long-term results after Preserflo microshunt implantation. IOP development, failure rates and complications were analyzed, comparing one-, two- and three-year results. 

Setting

Consecutive case series, retrospective single center single surgeon (F.R.) trial.

Methods

45 eyes of 36 patients with Preserflo microshunt (PM) implantation for glaucoma were included. The consecutive cases of all PM implantations between May 2021 and June 2023 were evaluated for IOP development, number of antiglaucomatous drugs, complications and additional surgery. Values were obtained preoperatively and one, two and three years after surgery. Failure rates were calculated for each postoperative year. IOP values were only counted, if no other surgery than bleb needling or bleb revision was done. If other surgery for IOP reduction was performed, or if IOP and antiglaucoma medication reached baseline levels, the PM implantation was classified as a failure.

Results

The mean IOP (± standard deviation) at baseline was 20.1±6.1 mmHg (n=45). 1, 2, and 3 years after PM implantation it was 13.6±4.2, 13.7±4.5, and 13.8±2.4 mmHg. The mean number of antiglaucomatous drugs at baseline was 2.5±1.4. 1, 2, and 3 years after, it was 0.6±1.2, 0.4±0.9, resp. 0.3±0.7. 14/45 eyes (31.1%) required bleb revision within 1st year. During first year, 11 of 45 (24.4%) eyes were failures. In the 2nd year 1 out of 19 eyes (5.2%) was a failure. During the 3rd year, no further eye failed. Early complications were present in 10/45 eyes (22.2%): At day 1, hyphema was present in 6/45 eyes (13.3%), hypotony and self-limiting choroidal detachment occurred in 3/45 eyes (6.6%), and one eye (2.2%) had severe choroidal bleeding.

Conclusions

Similar to trabeculectomy, the risk for bleb failure was very low two and three years after PM implantation, if a functional bleb was present one year after the operation. Until year three, no stent related complications like conjunctival defects or blebitis occurred in our cohort.